GenMab News

Denmark's Genmab will gain up to $2.1 billion in a licensing deal with GlaxoSmithKline for the HuMax-CD20 antibody for leukemia, far outstripping the numbers predicted by analysts. Genmab will get $102 million up front, a 10 percent equity investment worth $357 million and up to $1.6 billion in milestone payments. The therapy is in a late-stage trial for chronic lymphocytic leukemia and non-Hodkin's lymphoma and in mid-stage trials for rheumatoid arthritis and new cases of lymphocytic …